Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 3/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4436198 | 0.87 | EPHX1 (0.46) | P2RX7EPHX1NR3C2ARPTPN7 | |
| SCHEMBL5121133 | 0.84 | PPARD (0.45) | P2RX7EPHX1NR3C2ARPTPN7 | |
| SCHEMBL15881697 | 0.79 | EPHX1 (0.54) | P2RX7EPHX1NR3C2ARPTPN7 | |
| SCHEMBL4778248 | 0.79 | PIK3CA (0.47) | MDM2 | |
| SCHEMBL6213644 | 0.79 | P2RX7 (0.47) | P2RX7EPHX1NR3C2ARPTPN7 | |
| SCHEMBL5018902 | 0.78 | AR (0.44) | P2RX7EPHX1NR3C2ARPTPN7 | |
| SCHEMBL4725139 | 0.78 | CYP4F2 (0.46) | — | |
| SCHEMBL15262395 | 0.77 | EPHX2 (0.42) | P2RX7EPHX1NR3C2ARPTPN7 | |
| SCHEMBL1552615 | 0.76 | PTPN7 (0.42) | P2RX7EPHX1NR3C2ARPTPN7 | |
| SCHEMBL1552613 | 0.76 | PTPN7 (0.42) | P2RX7EPHX1NR3C2ARPTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221129-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008003753-A1 | PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY | BIOVITRUM AB (PUBL) (SE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221129-A1 | New compounds | SCD, SCD5, FASN | P2RX7 4875/4885EPHX1 1133/4885NR3C2 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.